MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -189.73 Million EUR | -25.6% |
| 2022 | -151.05 Million EUR | 70.64% |
| 2021 | -514.5 Million EUR | -625.59% |
| 2020 | 97.89 Million EUR | 195.03% |
| 2019 | -103.01 Million EUR | -83.39% |
| 2018 | -56.17 Million EUR | 19.55% |
| 2017 | -69.82 Million EUR | -15.64% |
| 2016 | -60.38 Million EUR | -505.23% |
| 2015 | 14.9 Million EUR | 594.61% |
| 2014 | -3.01 Million EUR | -122.61% |
| 2013 | 13.32 Million EUR | 585.94% |
| 2012 | 1.94 Million EUR | -76.36% |
| 2011 | 8.21 Million EUR | -10.66% |
| 2010 | 9.19 Million EUR | 2.59% |
| 2009 | 8.96 Million EUR | -31.85% |
| 2008 | 13.15 Million EUR | 14.63% |
| 2007 | 11.47 Million EUR | 90.36% |
| 2006 | 6.02 Million EUR | 28.9% |
| 2005 | 4.67 Million EUR | 1557.63% |
| 2004 | 282.11 Thousand EUR | 106.8% |
| 2003 | -4.14 Million EUR | 82.98% |
| 2002 | -24.37 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -314.96 Million EUR | -752.56% |
| 2023 Q1 | -43.88 Million EUR | -113.32% |
| 2023 Q4 | 48.26 Million EUR | 140.36% |
| 2023 Q3 | -119.6 Million EUR | -61.69% |
| 2023 FY | -189.73 Million EUR | -25.6% |
| 2023 Q2 | -73.96 Million EUR | -68.54% |
| 2022 Q3 | -122.9 Million EUR | 47.7% |
| 2022 Q4 | 329.44 Million EUR | 368.06% |
| 2022 Q1 | -185.31 Million EUR | 51.36% |
| 2022 FY | -151.05 Million EUR | 70.64% |
| 2022 Q2 | -234.99 Million EUR | -26.81% |
| 2021 Q2 | 20.9 Million EUR | 151.47% |
| 2021 FY | -514.5 Million EUR | -625.59% |
| 2021 Q3 | -112.77 Million EUR | -639.58% |
| 2021 Q1 | -40.6 Million EUR | -145.73% |
| 2021 Q4 | -381 Million EUR | -237.85% |
| 2020 Q1 | 195.51 Million EUR | 488.46% |
| 2020 Q4 | -16.52 Million EUR | 74.71% |
| 2020 Q3 | -65.34 Million EUR | -23.09% |
| 2020 FY | 97.89 Million EUR | 195.03% |
| 2020 Q2 | -53.08 Million EUR | -127.15% |
| 2019 Q4 | -50.32 Million EUR | -108.35% |
| 2019 Q1 | -22.66 Million EUR | 47.72% |
| 2019 Q2 | -5.85 Million EUR | 74.15% |
| 2019 FY | -103.01 Million EUR | -83.39% |
| 2019 Q3 | -24.15 Million EUR | -312.26% |
| 2018 Q1 | -19.48 Million EUR | -32.66% |
| 2018 Q4 | -43.36 Million EUR | -243.5% |
| 2018 Q2 | -23.53 Million EUR | -20.79% |
| 2018 FY | -56.17 Million EUR | 19.55% |
| 2018 Q3 | 30.21 Million EUR | 228.38% |
| 2017 Q1 | -15.04 Million EUR | 47.67% |
| 2017 FY | -69.82 Million EUR | -15.64% |
| 2017 Q4 | -14.69 Million EUR | 38.84% |
| 2017 Q3 | -24.01 Million EUR | -49.42% |
| 2017 Q2 | -16.07 Million EUR | -6.87% |
| 2016 Q2 | -11.61 Million EUR | -61.2% |
| 2016 FY | -60.38 Million EUR | -505.23% |
| 2016 Q4 | -28.74 Million EUR | -124.25% |
| 2016 Q3 | -12.81 Million EUR | -10.33% |
| 2016 Q1 | -7.2 Million EUR | 45.94% |
| 2015 Q4 | -13.33 Million EUR | -60.84% |
| 2015 FY | 14.9 Million EUR | 594.61% |
| 2015 Q3 | -8.28 Million EUR | -91.2% |
| 2015 Q2 | -4.33 Million EUR | -110.61% |
| 2015 Q1 | 40.85 Million EUR | 4166.9% |
| 2014 Q1 | 1.09 Million EUR | 130.81% |
| 2014 FY | -3.01 Million EUR | -122.61% |
| 2014 Q4 | -1 Million EUR | 60.94% |
| 2014 Q3 | -2.57 Million EUR | -388.23% |
| 2014 Q2 | -526.74 Thousand EUR | -148.31% |
| 2013 Q4 | -3.53 Million EUR | -68.04% |
| 2013 Q2 | 11.11 Million EUR | 41.45% |
| 2013 FY | 13.32 Million EUR | 585.94% |
| 2013 Q1 | 7.85 Million EUR | 148.22% |
| 2013 Q3 | -2.1 Million EUR | -118.95% |
| 2012 Q1 | -525.39 Thousand EUR | 89.05% |
| 2012 Q2 | -448.7 Thousand EUR | 14.6% |
| 2012 Q3 | -248.47 Thousand EUR | 44.63% |
| 2012 Q4 | 3.16 Million EUR | 1373.67% |
| 2012 FY | 1.94 Million EUR | -76.36% |
| 2011 Q1 | 18.82 Million EUR | 851.2% |
| 2011 FY | 8.21 Million EUR | -10.66% |
| 2011 Q2 | -3.81 Million EUR | -120.28% |
| 2011 Q4 | -4.79 Million EUR | -140.34% |
| 2011 Q3 | -1.99 Million EUR | 47.74% |
| 2010 Q4 | 1.97 Million EUR | 46.36% |
| 2010 FY | 9.19 Million EUR | 2.59% |
| 2010 Q1 | 3.19 Million EUR | 143.88% |
| 2010 Q2 | 2.67 Million EUR | -16.27% |
| 2010 Q3 | 1.35 Million EUR | -49.39% |
| 2009 Q3 | 2.61 Million EUR | 69.88% |
| 2009 Q4 | 1.3 Million EUR | -49.88% |
| 2009 FY | 8.96 Million EUR | -31.85% |
| 2009 Q2 | 1.53 Million EUR | -56.17% |
| 2009 Q1 | 3.5 Million EUR | 0.0% |
| 2008 FY | 13.15 Million EUR | 14.63% |
| 2007 FY | 11.47 Million EUR | 90.36% |
| 2006 FY | 6.02 Million EUR | 28.9% |
| 2005 FY | 4.67 Million EUR | 1557.63% |
| 2004 FY | 282.11 Thousand EUR | 106.8% |
| 2003 FY | -4.14 Million EUR | 82.98% |
| 2002 FY | -24.37 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -10883.452% |
| CSL Limited | 2.64 Billion USD | 107.181% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -153.104% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -2785.204% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -69297.517% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 458.131% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 391.303% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -10321.932% |
| Mesoblast Limited | -87.95 Million USD | -115.715% |
| Marizyme, Inc. | -65.34 Million USD | -190.349% |
| Genus plc | 7.9 Million USD | 2501.699% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -1642.001% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -5013.807% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -2045.344% |
| ContraFect Corporation | -65.15 Million USD | -191.213% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -3783.171% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -36.48 Million USD | -420.024% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -2254.115% |
| MultiCell Technologies, Inc. | -380.07 USD | -49920756.421% |
| Accustem Sciences Inc. | -3.74 Million USD | -4964.415% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -267.048% |
| EV Biologics, Inc. | -1.26 Million USD | -14873.491% |
| Q BioMed Inc. | -2.05 Million USD | -9145.887% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -4982.62% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -7869.112% |
| Biomind Labs Inc. | -1.21 Million USD | -15524.741% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -2300.759% |
| Skye Bioscience, Inc. | -37.64 Million USD | -404.012% |
| SQZ Biotechnologies Company | -79.46 Million USD | -138.767% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -1266821.735% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -2617.151% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -6459.763% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -1095.444% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -29901.913% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -1698.769% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -8644.261% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -3161.577% |
| GB Sciences, Inc. | -1.36 Million USD | -13833.862% |
| Alpha Cognition Inc. | -13.77 Million USD | -1277.624% |
| argenx SE | -295.05 Million USD | 35.695% |
| HST Global, Inc. | -146.21 Thousand USD | -129668.278% |
| Halberd Corporation | -79.67 Thousand USD | -238032.184% |
| Enzolytics Inc. | -2.17 Million USD | -8616.07% |
| Resverlogix Corp. | -3.61 Million USD | -5155.795% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -5882.596% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -203.095% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -217.678% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 193706.326% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -6016.969% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 2840.005% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -9633.708% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -4675.599% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -6169.852% |
| AVAX Technologies, Inc. | -6.41 Million USD | -2858.288% |
| ONE Bio Corp. | 8.67 Million USD | 2286.731% |
| Zenith Capital Corp. | -10.59 Million USD | -1690.621% |
| Genscript Biotech Corporation | -95.47 Million USD | -98.722% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -816241.963% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -4476.39% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -313818.405% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -9362.51% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -10712.476% |
| Agentix Corp. | -1.37 Million USD | -13706.773% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.3 Million USD | -5636.661% |
| Helix BioMedix, Inc. | -1.05 Million USD | -17866.284% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -4868.164% |
| BioStem Technologies, Inc. | -8.48 Million USD | -2136.645% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -42887.659% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -14107.713% |
| LadRx Corporation | 400.44 Thousand USD | 47481.075% |
| Cell Source, Inc. | -5.32 Million USD | -3465.62% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -45566.375% |
| Regen BioPharma, Inc. | 1.02 Million USD | 18637.637% |
| Regen BioPharma, Inc. | 1.02 Million USD | 18637.637% |
| NovAccess Global Inc. | -4.76 Million USD | -3878.334% |
| Affymax, Inc. | -14.42 Million USD | -1215.406% |
| Itoco Inc. | -1.86 Million USD | -10051.67% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -4170.854% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -11268.137% |
| CytoDyn Inc. | -49.84 Million USD | -280.679% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -239969.59% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -83070.427% |
| Qrons Inc. | -789.34 Thousand USD | -23936.856% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -20051.711% |
| SYBLEU INC | -180.3 Thousand USD | -105130.166% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -8988.271% |
| Rebus Holdings, Inc. | -1.02 Million USD | -18501.392% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -11664.733% |
| Mobile Lads Corp. | -2.26 Million USD | -8283.107% |
| International Stem Cell Corporation | -131 Thousand USD | -144735.266% |
| Bioxytran, Inc. | -4.28 Million USD | -4333.04% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -349498.686% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -7398.643% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -294.688% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -8875.128% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -24197.267% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -5889.085% |
| Neutra Corp. | -233.46 Thousand USD | -81168.798% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -835.066% |
| PureTech Health plc | -65.69 Million USD | -188.802% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -792.173% |
| IXICO plc | -1.17 Million USD | -16006.469% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -1811.294% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -232.121% |
| CSL Limited | 2.64 Billion USD | 107.181% |
| Cellectis S.A. | -103.17 Million USD | -83.898% |